Evidence map›Paper›PMID 34816021›Full record

ArticleJournal of clinical tuberculosis and other mycobacterial diseases2021

Rifampicin susceptibility discordance between Xpert MTB/RIF G4 and Xpert Ultra before MDRT-TB treatment initiation: A case report from Uganda.

Willy Ssengooba, Kevin Komakech, Sharon Namiiro, Henry Byabajungu, Joanitah Nalunjogi, Winceslaus Katagira, Ivan Kimuli, Moses L Joloba, Susan Adakun, Lydia Nakiyingi and 2 more

Open access · goldAbstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of clinical tuberculosis and other mycobacterial diseases, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 85% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 0 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 5 institutions in 2 countries.

Willy SsengoobaMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Kevin KomakechMakerere University, Department of Medical Microbiology, Mycobacteriology (BSL-3) Laboratory, P.O.BOX 7072, Kampala, Uganda.
Sharon NamiiroMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Henry ByabajunguNational TB Reference Laboratory, Ministry of Health, Kampala, Uganda.
Joanitah NalunjogiMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Winceslaus KatagiraMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Ivan KimuliMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Moses L JolobaMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Susan AdakunMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Lydia NakiyingiInfectious Diseases Institute, Makerere University, Kampala, Uganda.
Gabriela TorreaUnit of Mycobacteriology, Department of Biomedical Sciences, Institute of Tropical Medicine, Antwerp, Belgium.
Bruce J KirengaMakerere University Lung Institute, College of Health Sciences, Makerere University, Kampala, Uganda.
Makerere University · UGInfectious Diseases Institute · UGInstituut voor Tropische Geneeskunde · BEMinistry of Health · UGMulago Hospital · UG

Funding

NURTURE:Research Training and Mentoring Program for Career Development of Faculty at Makerere University College of Health SciencesD43TW010132 · FIC · MAKERERE UNIVERSITY COLLEGE OF HEALTH SCIENCES · PI SEWANKAMBO, NELSON K · 2015 to 2019
$4.3M
FIC NIH HHS D43 TW010132
6 · The paper itself

Abstract

Tuberculosis (TB) resistance to rifampicin, the most powerful drug leads to increase in mortality. Globally, half a million new patients develop such resistant TB each year, coupled with both inappropriate diagnosis and treatment initiation. We report a case of rifampicin resistant

Indexed as

DiscordanceG4RifampicinULTRAXpertMTB/RIF

Identifiers

PMID34816021
PMCPMC8592849
OpenAlexW3214434954

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.